Humacyte shares rise 12.05% after-hours as analyst estimates improve 15.9% and outperform medical sector.

Humacyte, Inc. (HUMA) surged 12.05% in after-hours trading following a report highlighting its outperformance against the broader Medical sector and improved earnings expectations. The stock has gained 12.4% year-to-date, outpacing the sector’s 7.6% average return, while its Zacks Consensus Estimate for full-year earnings rose 15.9% in the past quarter, indicating stronger analyst sentiment. The firm’s Zacks Rank of #2 (Buy) further underscores its favorable outlook. The after-hours jump aligns with the positive revision in earnings forecasts and relative performance against peers, suggesting renewed investor confidence in its biomedical industry position.